" class="no-js "lang="en-US"> Strand Therapeutics Presents Data on mRNA Therapy at AACR
Friday, June 09, 2023

Strand Therapeutics Presents Preclinical Data on Programmable mRNA Therapy STX-001 at AACR 2023

Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, announced today preclinical data from its programmable mRNA therapy STX-001, a multi-modal synthetic self-replicating mRNA technology that delivers a prolonged and locally-acting IL-12 cytokine to the tumor microenvironment.

Immunotherapy has revolutionized cancer treatment, but only a minority of patients experience durable clinical responses. One of the reasons for this limited efficacy is the failure of immune checkpoint inhibitors to sufficiently activate and recruit T cells into the tumor microenvironment. STX-001, when delivered directly to the tumor, induces a highly immunogenic tumor cell death while the mRNA-encoded IL-12 payload promotes recruitment of effector T cells and NK cells into the tumor microenvironment. STX-001 shows promise as a new approach to improve the efficacy of current immunotherapies for solid tumors. STX-001’s self-replicating mRNA technology induces immunogenic tumor cell death and promotes recruitment of T cells and NK cells to the tumor microenvironment as well as their activation.

“Our programmable mRNA therapy STX-001 overcomes the limitations of current immunotherapy to improve clinical responses to solid tumors. The major breakthrough is that we’ve shown for the first time our therapy enables the delivery of therapeutic quantities of IL-12 with greater efficacy than conventional mRNA,” said Tasuku Kitada, Ph.D., President and Head of R&D of Strand Therapeutics.

“This early data also shows that STX-001 induces durable anti-tumor responses and enhances efficacy when combined with PD-1/PD-L1 checkpoint inhibitors. STX-001 represents a promising new approach for the treatment of solid tumors, and we look forward to advancing this candidate into clinical trials later this year,” said Prashant Nambiar, DVM, Ph.D., Senior Vice President, Research and Translational Development.

  1. Charles River and INADcure Announce Gene Therapy Manufacturing Collaboration Read more
  2. Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease Read more
  3. Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas Read more
  4. Quell Therapeutics Signs Agreement with AstraZeneca to Develop and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases Read more
  5. Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 Read more